NASDAQ:CRSP CRISPR Therapeutics Q2 2026 Earnings Report $51.72 -0.54 (-1.03%) Closing price 09/11/2026 04:00 PM EasternExtended Trading$51.76 +0.05 (+0.09%) As of 09/11/2026 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast CRISPR Therapeutics EPS ResultsActual EPS-$0.94Consensus EPS -$1.19Beat/MissBeat by +$0.25One Year Ago EPS-$2.40CRISPR Therapeutics Revenue ResultsActual Revenue$10.18 millionExpected Revenue$7.45 millionBeat/MissBeat by +$2.73 millionYoY Revenue Growth+1,033.30%CRISPR Therapeutics Announcement DetailsQuarterQ2 2026Date8/3/2026TimeAfter Market ClosesConference Call DateMonday, August 3, 2026Conference Call Time4:00PM ETUpcoming EarningsCRISPR Therapeutics' Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, November 3, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) CRISPR Therapeutics Earnings HeadlinesAxsome Therapeutics vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?September 11 at 5:33 PM | finance.yahoo.comSet Yourself Up for a Strong 2027: 2 Pharmaceutical Stocks to Buy in SeptemberSeptember 11 at 7:32 AM | fool.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.September 13 at 1:00 AM | Porter & Company (Ad)Rocket Pharmaceuticals (RCKT) Up 6% Since Last Earnings Report: Can It Continue?September 11 at 2:31 AM | finance.yahoo.comWhy CRISPR Therapeutics Stock Rocked the Market Last MonthSeptember 8, 2026 | fool.comWhere Will CRISPR Therapeutics Stock Be in 5 Years?September 8, 2026 | fool.comSee More CRISPR Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CRISPR Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CRISPR Therapeutics and other key companies, straight to your email. Email Address About CRISPR TherapeuticsCRISPR Therapeutics (NASDAQ:CRSP) (NASDAQ: CRSP) is a biotechnology company focused on developing gene-editing medicines using CRISPR/Cas9 technology. The company’s programs are designed to modify disease-associated genes in human cells, with the goal of treating serious conditions across hematology, oncology, autoimmune disease and regenerative medicine. Its most advanced product is Casgevy (exa-cel), an autologous cell therapy developed in collaboration with Vertex Pharmaceuticals. Casgevy uses CRISPR/Cas9 gene editing to modify a patient’s blood stem cells and is approved in several markets for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia. The product was among the first medicines based on CRISPR gene-editing technology to receive regulatory approval. Founded in 2013, CRISPR Therapeutics operates internationally, with corporate activities in Switzerland and the United States. In addition to its hemoglobinopathy program, the company is advancing investigational therapies in areas such as cancer, type 1 diabetes and immune-mediated diseases through both internal research and collaborations. Its scientific origins are associated with CRISPR pioneers Emmanuelle Charpentier and Rodger Novak, while Samarth Kulkarni has served as the company’s chief executive officer.View CRISPR Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/07 - 09/11Kroger’s Textbook Entry for Buy-and-Hold InvestorsOracle’s AI Spending Is Still Huge, But the Payoff Is Starting to Show in EarningsPlanet Labs Has Fallen Back to Earth, But Wall Street Still Sees a ReboundAmgen Drops 10% on a Trial It Didn't Even RunOil Above $100 Is Creating a New Opportunity Beyond the Major ProducersAST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing Window Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
